GovChime
Notice ID: 3a36d74d2c844e24a7b46746f052d065Presolicitation

Recombinant Human Interleukin-4 (IL-4), GMP Grade (CC: 11200) (50 mcg) from CellGenix USA

Archived on July 23, 2020. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
9:00 AM UTC−04:00
Posted
June 25, 2020
Notice type
Presolicitation
NAICS
325199: All Other Basic Organic Chemical Manufacturing
Agency
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH

Notice details

Office
NATIONAL INSTITUTES OF HEALTH - CC
Place of performance
Bethesda, MD, 20892
Last updated
Dec 4, 2025

Identifiers

Solicitation number
NIH-CC-20-010608
Notice ID
3a36d74d2c844e24a7b46746f052d065

Description

THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Institutes of Health (NIH), Clinical Center (CC), Pharmacy Development Service (PDS), intends to enter into a contract on a sole source basis, under the authority of 41 U.S.C. 253 (c) (1) and FAR 6.302-1(a) (2) (ii) and HHSAR 306.302-1 (a) (2) (ii), a contract to purchase 105 vials of a biological product; Recombinant Human Interleukin 4 (rec.hu.IL-4). This item is required to restock supplies for ongoing NIH/NCI protocol. It is essential to the integrity of this protocol that the source of the rec.hu.IL-4 come from the same source so as not to introduce variables harmful to the findings of the protocol. Vaccine preparation for this protocol is based on the procedures developed and utilized for years using the CellGenix product. If there are other sources able to supply the required material, they must respond by submitting a capability statement within 10 days of publication of this synopsis. This notice of intent is not a request for competitive proposals. However, all proposals received prior to the closing date of this synopsis will be considered solely for the purpose of determining whether to conduct a competitive procurement. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. RESPONDENTS MAY SUBMIT THEIR CAPABILITY STATEMENTS VIA E-MAIL TO THE POINT OF CONTACT LISTED IN THIS NOTICE OF INTENT SYNOPSIS. The Clinical Center (CC) plans to procure, on a sole source basis, from CellGenix GmbH, US Operations; 303 Main Stret, Suite 100-C; Antioch, IL 60002. The Recombinant Human Interleukin-4 (IL-4), GMP Grade (CC: 11200) (50 mcg) previously purchased from this company is currently in use with NIH Clinical Center patients in ongoing protocols. The purchase of this medication from CellGenix will allow for the continuity of the protocols involved. This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.106-1(b)(2) and 13.501-(a)(1) to use simplified procedures for commercial acquisitions. The North American Industry Classification System Code is 325199 and the business size standard 750 employees. Only one award will be made as a result of this solicitation. This will be a firm fixed price type contract. To the maximum extent possible, please submit non-proprietary information. Any proprietary information submitted should be identified as such and will be properly protected from disclosure. Interested Offerors should submit their capability statement not exceeding twenty (20) pages in length, excluding standard brochures. SUBMISSIONS ARE DUE no later than 9:00 a.m., Eastern Time, July 8, 2020. The capabilities response shall be e-mailed to: Lisa.Schaupp@nih.gov . All information received in response to this notice that is marked Proprietary will be handled accordingly. Information provided in response to this notice will be used to assess alternatives available for determining how to proceed in the acquisition process. This notice is part of Government Market Research, a continuous process for obtaining the latest information on the commercial status of the industry with respect to their current and near-term abilities. The information provided herein is subject to change and in no way binds the Government to solicit for or award a competitive contract. The NIH/CC will use the information submitted in response to this notice at its discretion and will not provide comments to any submission; however, the content of any responses to this notice may be reflected in subsequent solicitation. NIH/CC/OPC reserves the right to contact any respondent to this notice for the sole purpose of enhancing NIH/CC/OPC 's understanding of the notice submission. This announcement is Government market research, and may result in revisions in both its requirements and its acquisition strategy based on industry responses. It is emphasized that this is a notice for planning and information purposes only and must not be construed as a commitment by the government to enter into a contractual agreement, nor will the government pay for information solicited. Responses to this Notice of Intent shall be submitted before the closing date and time to the attention of the Contract Specialist Lisa Schaupp (Lisa.Schaupp@nih.gov).

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:NIH-CC-20-010608
  1. Pre-Solicitation

Formal solicitation typically follows within 30–60 days. (estimate)

  1. Pre-SolicitationCurrentJun 25, 2020

    Recombinant Human Interleukin-4 (IL-4), GMP Grade (CC: 11200) (50 mcg) from CellGenix USA

    Notice 3a36d74d2c844e24a7b46746f052d065 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
The 316 Civil Engineers Squadron is looking to establish a secure, compliant, and rapid-response supply chain IDIQ for liquid (Potassium Acetate) and solid (Sodium Acetate) airfield pavement deicers to maintain safe runway and taxiway conditions during winter operations for a 5-year ordering period. A Certificate of Analysis (CoA) demonstrating compliance with the Society of Automotive Engineers Aerospace Material Specification (SAE AMS) SAE AMS 1435 or SAE AMS 1431 must accompany every single shipment delivery. Delivery Orders will be issued on an as-needed basis IAW the Statement of Work (SOW).Please see Attachment 1: SOW for more information on specifications.Any questions must be emailed to the POCs no later than 10 November 2026 at 1200 Eastern Time. All questions and answers will be posted on SAM.gov.Please submit your priced response to this RFQ in a separate pdf document following the Instructions to Offeror section with all the necessary and up-to-date company information. Please fill out the information in the table of the Combo Solicitation in your priced RFQ response.
-Combined Synopsis11/16/2026
-Combined Synopsis11/16/2026
Naval Surface Warfare Center Indian Head Division (NSWC IHD), located in Indian Head, Maryland, is interested in establishing Blanket Purchase Agreements (BPAs) with companies that provide standard commercial supplies and services at competitive prices in Classification: PSC/FSC CODE 6810, NAICS 325199, CHEMICALS PSC/FSC Code 6830, NAICS 325199, GASES: COMPRESSED AND LIQUEFIED We are looking for the following chemicals: Argon Nitrogen Helium Oxygen Air Nitrous Oxide (dip tube tanks) Methane Ethylene Ethane Hydrogen BPA Calls will not exceed the Simplified Acquisition Threshold and Offerors will compete at the call level. Interested companies must (have/include): Cover sheet with the official company name, cage code, and point of contact including name, phone number, and email address. Documentation addressing the capabilities and expertise. Complete and return a price list, if applicable. BPA's will be awarded on the basis of positive Past Performance. Interested vendors should provide a minimum of three Past Performance References (attached). The Past Performance references shall include name of the business/organization, address, and contract /order number, and award amount, point of contact, telephone number and description of the item. The Past Performance will be evaluated based upon Customer Satisfaction, Timeliness, Technical Success, Program Management, and Quality. The government reserves the right to use additional references if available. An active account in the Procurement Integrated Enterprise Environment (PIEE formerly WAWF) at https://pieef.eb.mil to enter invoices and receiving reports, or credit card as a method of payment. An active account in System for Award Management (SAM https://www.sam.gov) Important Notes: *This is a small business set-aside. If you possess a GSA contract, please note your GSA contract number in your response. *Vendors who are found to have technical and past performance merit will be issued a Master BPA to be able to bid on future requirements. *Price lists and catalog prices can be provided as they may help with direct award under the $10k threshold. UPATED 9/30/2024 The Government is updating the required submission deadlines and changing the award dates. The following is the new guidelines: The Government intends to issue Master BPAs on a 6-month rotation through June 2029. To be considered for a June award, Interested Vendors should provide documentation and references to my email barbara.j.grinder.civ@us.navy.mil no later than 30 April. For a December award, interested vendors should provide documentation and references by email to Barbara.j.grinder.civ@us.navy.mil no later than 31 October. PREVIOUS DATES *The Government intends to issue Master BPAs on 6 month rotation through February 2029. To be considered for a February award, interested vendors should provide documentation and references to by email to Barbara.j.grinder.civ@us.navy.mil no later than 31 December. For an August award, interested vendors should provide documentation and references by email to Barbara.j.grinder.civ@us.navy.mil no later than 30 June. *The Government reserves the right to consider past performance information available from other sources, including, but not limited to, information in the Contractor Performance Assessment Reporting System (CPARS), the Past Performance Information Retrieval System (PPIRS https://www.ppirs.gov), and the Federal Awardee Performance and Integrity Information System (FAPIIS). The Points of Contact for this request are: Barbara Grinder – Barbara.j.grinder.civ@us.navy.mil Brandi Sorzano – brandi.l.sorzano.civ@us.navy.mil TPOC/TAS – (Lynn Tarburton) – lynn.m.tarburton.civ@us.navy.mil **Attachments** All announcements should include 3 Past Performance Reference. (Sheet attached). ***Amendment 0001*** At this time, IHD is pausing the rolling admissions process for additional BPA vendors. If your company submitted a package for evaluation, when the rolling admissions process is reopened, your company will be afforded an opportunity to submit a new package or resend your prior package for consideration. Our IHD team is exploring opportunities to automate the BPA interest and evaluation process. We look forward to sharing the new process enhancements with you in the future. Please do not contact the individuals listed below regarding the BPA status or process at this time. Our IHD_BPA@us.navy.mil inbox will be used for all future inquiries.
-Combined Synopsis11/11/2028
Acquisition Description: This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Cardinal Health. This requirement will be sole sourced to Cardinal Health under FAR 13.501(a) or 8.405-6 (b) - sole source requirements. The National Institutes of Health (NIH) Clinical Center (CC) (NIH-CC or “Program”) is a clinical research hospital providing all medical services for patients participating in human research protocols of the NIH. The CC Pharmacy department provides a range of pharmaceutical care services to inpatients and outpatients enrolled in clinical trials. The CC Pharmacy department is responsible for acquiring the supply of medications required for patient care. The NIH-CC has a pharmacy center that requires Sirturo (Bedaquiline) drug tablets for patient care. Sirturo is supplied in the following forms: 100 mg tablets in 188 count bottles and 20 mg tablets in 60 count bottles. Various different quantities are needed every year. Based on Program’s purchase history in the past, and factoring in the anticipated patient enrollment, Program expects to need approximately 12 - 36 bottles of each type of Sirturo® bottles per year. Justification: Only this Sirturo medication can be accepted as there are no substitutes for this medication. The manufacturer (Janssen Therapeutics) has designated Cardinal Health (DBA Metro Medical Supply) as the sole distributor of Sirturo in the U.S. Previous acquisitions and research indicated that this requirement should be a sole source requirement. For the previous acquisitions, Notice of Intent notices were posted on SAM.gov. Cardinal Health/Metro Medical was the only sole source provider. In order to confirm this is still applicable, this requirement was previously posted on SAM.gov as an RFQ under full and open competition under RFQ-CC-24-008485. No other companies responded, and it was confirmed by this posting that they are the sole source vendor. Previous acquisitions and research revealed this requirement should be a sole source requirement. More recently, a Request for Quotes was posted under RFQ-CC-24-008485 and it was reconfirmed that Cardinal Health/Metro Medical is the sole source vendor as they are the official authorized reseller of this equipment via their relationship with the manufacturer. Thus, Cardinal Health/Metro Medical is the only responsible and authorized source for Sirturo. Requirements: SIRTURO (BEDAQUILINE) 100 mg tablet in 188-count bottles (NDC# 59676070101) SIRTURO (BEDAQUILINE) 20 mg tablet in 60-count bottles (NDC#59676070260) Period of performance/Date of Delivery: Within 30 days of award, or mutually agreed upon. Place of Performance or Delivery: Place of Performance: NIH Clinical Center in Bethesda, MD The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-27-000056) by 04:00 PM eastern standard time on 11/11/2026 to: lu-chang.lu@nih.gov All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
-Pre-Solicitation11/11/2026
(i)This is a combined synopsis/solicitation for commercial items prepared in accordancewith the format in FAR Subpart 12.6, as supplemented with additional information includedin this notice. This announcement constitutes the only solicitation; proposals are beingrequested, and a separate written solicitation will not be issued. (ii)The solicitation number is 75N98027Q00017. This solicitation is issued as a Notice ofIntent (NOI) for a non-competitive combined synopsis/solicitation to award a contract orpurchase order without providing for full and open competition (including brand-name, ifapplicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a purchase order on a non-competitive basis to Purdue University, Purdue Institute for Drug Discovery (DRUG), 575 Stadium Mall Drive, West Lafayette, IN 47907, for the synthesis, scale-up, and characterization of lead Spleen Tyrosine Kinase (SYK) inhibitors in support of the NIH Bench-to-Bedside study "Developing Red Cell-Specific Spleen Tyrosine Kinase (SYK) Inhibitors for Treating Sickle Cell Disease." Rationale for non-competitive award: The proposed acquisition is a continuation of project-specific medicinal chemistry work under the NIH Bench-to-Bedside study "Developing Red Cell-Specific Spleen Tyrosine Kinase (SYK) Inhibitors for Treating Sickle Cell Disease." Dr. Philip S. Low's laboratory at Purdue University is the identified extramural medicinal chemistry collaborator for this project and has performed the prior design and synthesis work associated with the SYK inhibitor candidates being advanced under the study. The Year 1 requirement is specifically for the synthesis, scale-up, and characterization of lead SYK inhibitors S1115 and S1213 for subsequent biological evaluation by NIH investigators. Purdue possesses the project-specific knowledge and experience associated with these compounds. Use of another source would require duplication of prior research before the source could continue the current effort, resulting in delay and technical risk. Based on these circumstances, Purdue University is the only source reasonably available to perform this specific Year 1 requirement. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01, effective 03/13/2026. (iv) The associated NAICS code is 325411, Medicinal and Botanical Manufacturing, and the small business size standard is 1,250 employees. This requirement is not set aside for small business.
-Combined Synopsis11/04/2026

Additional Details

Solicitation Number

NIH-CC-20-010608

Archive Date

Jul 23, 2020

Office Address

BETHESDA, MD, 20892